Cerebrospinal fluid and plasma distribution of myo-inositol and other polyols in Alzheimer disease

Clinical Chemistry

Volumn 42, Issue 2, 1996, Pages 298-302

  Shetty, H Umesha ^a   Holloway, Harold W ^a   Schapiro, Mark B ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

carbohydrate metabolism; gas chromatography mass spectrometry

Indexed keywords

1,5 ANHYDROSORBITOL; INOSITOL; POLYOL;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CARBOHYDRATE METABOLISM; CEREBROSPINAL FLUID; CHROMOSOME 21; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN SYNDROME; FEMALE; GAS CHROMATOGRAPHY; HUMAN; MALE; MASS SPECTROMETRY; PLASMA;

EID: 0030038202     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/42.2.298     Document Type: Article

References (28)

1. Cohen MP. The polyol paradigm and complications of diabetes. New York: Springer-Verlag, 1987:59pp.
2. Clements RS Jr, DeJesus PV Jr, Winegrad AI. Raised plasma-myoinositol levels in uraemia and experimental neuropathy. Lancet 1973;i:1137-41.
3. Fisher SK, Heacock AM, Agranoff BW. Inositol lipids and signal transduction in the nervous system: an update. J Neurochem 1992;58:18-38.
4. +/myo-inositol cotransport in rat cortical astrocytes. Glia 1994;12:35-43.
5. Shetty HU, Schapiro MB, Holloway HW, Rapoport SI. Polyol profiles in Down syndrome: myo-inositol, specifically, is elevated in the cerebrospinal fluid. J Clin Invest 1995;95:542-6.
6. Shonk T, Ross BD. Role of increased cerebral myo-inositol in the dementia of Down syndrome. Magn Reson Med 1995;33:858-61.
7. +/myo-inositol cotransporter gene (SLC5A3): molecular cloning and localization to chromosome 21. Genomics 1995;25:507-13.
8. Shonk TK, Moats RA, Gifford P, Michaelis T, Mandigo JC, Izumi J, Ross BD. Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology 1995;195:65-72.
9. Stokes CE, Hawthorne JN. Reduced phosphoinositide concentrations in anterior temporal cortex of Alzheimer-diseased brains. J Neurochem 1987;48:1018-21.
10. 2+ mobilization is altered in fibroblasts from patients with Alzheimer disease. Proc Natl Acad Sci U S A 1994;91:534-8.
11. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994:123-63.
12. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44.
13. Folstein MF, Folstein SE, McHugh PR. MiniMental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
14. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985;42:1097-105.
15. Hachinski VC, Iliff LD, Zilhka E, Du Boulay GH, McAllister VL, Marshall J, et al. Cerebral blood flow in dementia. Arch Neurol 1975;32:632-7.
16. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-96.
17. Schapiro MB, Atack JR, Hanin I, May C, Haxby JV, Rapoport SI. Lumbar cerebrospinal fluid choline in healthy aging and in Down's syndrome. Arch Neurol 1990;47:977-80.
18. Shetty HU, Holloway HW, Rapoport SI. Capillary gas chromatography combined with ion trap detection for quantitative profiling of polyols in cerebrospinal fluid and plasma. Anal Biochem 1995; 224:279-85.
19. Quan-Ma R, Wells HJ, Wells WW, Sherman FE, Egan TJ. Galactitol in the tissues of a galactosemic child. Am J Dis Child 1966;112: 477-8.
20. Rapoport SI. Passage of proteins from blood to cerebrospinal fluid. In: Wood JH, ed. Neurobiology of cerebrospinal fluid, Vol. 2. New York: Plenum Press, 1983:233-45.
21. Hauser G, Finelli VN. The biosynthesis of free and phosphatide myo-inositol from glucose by mammalian tissue slices. J Biol Chem 1963;238:3224-8.
22. Spector R. myo-Inositol transport through the blood-brain barrier. Neurochem Res 1988;13:785-7.
23. Spector R, Lorenzo AV. myo-Inositol transport in the central nervous system. Am J Physiol 1975;228:1510-8.
24. Barkai AI. myo-Inositol turnover in the intact rat brain: increased production after d-amphetamine. J Neurochem 1981;36:1485-91.
25. Moats RA, Ernst T, Shonk TK, Ross BD. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn Reson Med 1994;32:110-5.
26. Rapoport SI. Topography of Alzheimer's disease: involvement of association neocortices and connected regions; pathological, metabolic and cognitive correlations; relation to evolution. In: Rapoport SI, Petit H, Leys D, Christen Y, eds. Imaging, cerebral topography and Alzheimer's disease. Research and perspectives in Alzheimer's disease, Fondation Ipsen. Berlin: Springer-Verlag, 1990:1-17.
27. Sherman WR, Packman PM, Laird MH, Boshans RL. Measurement of myo-inositol in single cells and defined areas of the nervous system by selected ion monitoring. Anal Biochem 1977;78:119-31.
28. Levine J, Rapaport A, Lev L, Bersudsky Y, Kofman O, Belmaker RH, et al. Inositol treatment raises CSF inositol levels. Brain Res 1993;627:168-70.